Drug Profile
Tisotumab vedotin companion diagnostic - Genmab
Alternative Names: HuMax-TF-ADC companion diagnostic - GenmabLatest Information Update: 13 Jul 2021
Price :
$50
*
At a glance
- Originator Genmab
- Developer Roche Tissue Diagnostics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 13 Jul 2021 Ventana Medical Systems is now called Roche Tissue Diagnostics
- 28 Jul 2018 No recent reports of development identified for research in Solid-tumours(Diagnosis) in Denmark
- 03 Apr 2014 Ventana Medical Systems and Genmab enter into an agreement to develop an immunohistochemistry companion diagnostic test to select patients for HuMax®-TF-ADC